What is it about?
Each year, over five million people die worldwide from stroke. One out of four strokes is recurrent placing huge burden on health care system. Despite new evidences on how to best treat patients with ischemic stroke, stroke recurrence remains unacceptably high. Therefore, there is a great need for novel thechnologies and markers to prevent hospital readmissions due to recurrent stroke. A post-stroke care coordination program in the first year after a stroke is vital. Therefore, a personalised clinical pathway ensuring that patients receive personalized treatment and care remotely after discharge is utmost. In our research, we focused on personalised antiplatelet regimens based on genetic information, clinical and platelet characteristics. Post ischemic stroke patients are commonly on antiplatelet therapy (aspirin, clopidogrel monotherapy or dual antiplatelet treatment, DAPT). Despite such interventions, the treatment failure leading to recurrent stroke is often explained by the phenomenon called high-on-treatment platelet reactivity (HTPR). There are many attempts currently being made around the world to make translational research findings usable in clinical settings to achieve individualised antiplatelet therapy. Nevertheless, the recognition of HTPR remained unsolved. Measurement of ex vivo platelet function in patients on antiplatelet therapy would potentially enable physicians to tailor antiplatelet strategies to an individual. As such a new and innovative modification of Electric Impedance Aggregometry measurement was published in Clinical Hemorheology and Microcirculation (Ezer E, et al. A novel approach of platelet function test for prediction of attenuated response to clopidogrel) and in Frontiers in Neurology (Schrick D, et al. Novel predictors of future vascular events in post-stroke patients). The ex vivo platelet aggregation induced by an agonist is expressed by the area under the curve (AUC) detected by Multiplate impedance aggregometer.The measurement was performed not only in the whole blood, but as a novelty from the lower and upper blood fractions separated after 1-hour gravity sedimentation by the analogy with erythrocyte sedimentation rate. Importantly, a greater AUC (≥70 as a cut-off value) from the separated upper blood sample after 1-hour gravity sedimentation emerged as a novel independent predictor of future stroke episodes, while clopidogrel resistance based solely on Multiplate electrode aggregometry from the whole blood was not able to predict recurrent stroke in a prospective, but small study. Based on atomic force microscopy, the more reactive, ascending platelets (presumably detected with greater AUC by Multiplate) were found to be larger in volume, suggesting a link between the function and the size of platelets. In accordance, platelets with a higher mean volume showed an association with high residual platelet reactivity after conventional dual antiplatelet therapy in patients with coronary artery disease reported by others.
Featured Image
Why is it important?
This work highlights that antiplatelet therapy should be guided by novel platelet function test.
Perspectives
Read the Original
This page is a summary of: A novel approach of platelet function test for prediction of attenuated response to clopidogrel, Clinical Hemorheology and Microcirculation, December 2019, IOS Press,
DOI: 10.3233/ch-190580.
You can read the full text:
Resources
Prevention of Non-Cardiogenic Ischemic Stroke: Towards Personalized Stroke Care
Despite diagnostic advances and new evidence on how to best treat patients with ischemic stroke, the risk of stroke recurrence remains unacceptably high. Therefore, there is a great need for novel therapies and markers to guide risk stratification, reveal stroke aetiology, identify patients who may benefit most from interventions, predict risk for another stroke, and recognize the risk of short-term complications or unfavorable long-term outcomes. The purpose of this chapter is to provide an update on: (i) emerging markers in atherothrombotic stroke; (ii) role of systemic inflammation in contributing to stroke occurrence; (iii) the main antiplatelet agents that have been successfully used in the secondary prevention of non-cardiogenic ischemic stroke and transient ischemic attack; (iv) screening for high-on-treatment platelet reactivity after stroke; and (v) to explore novel and effective antiplatelet strategies for the secondary prevention of ischemic stroke. Rising questions such as indications for antiplatelet therapy after a successful recanalisation following acute ischemic stroke should be answered in the future to optimize outcomes. Finally, we aim to focus on personalized antiplatelet regimens and current translational research findings in this field.
Secondary Prophylaxis of Stroke from a Multidisciplinary Perspective
Each year, over five million people die worldwide from stroke. One out of four strokes is recurrent placing huge burden on health care system. Despite new evidences on how to best treat patients with ischemic stroke, stroke recurrence remains unacceptably high. Therefore, there is a great need for novel thechnologies and markers to prevent hospital readmissions due to recurrent stroke. This paper attempts to list possible options in the areas of prevention, early detection, monitoring, and personalised therapy.
Contributors
The following have contributed to this page